PCS Research Technology Unveils BiotechTracker Healthcare Research Service
Interactive Web-Based Service for Institutional Investors Combines Comprehensive Analysis of Developmental Drugs with Equity Valuation Tools
SAN DIEGO--(BUSINESS WIRE)--Oct. 10, 2002-- PCS Research Technology, Inc. (OTCBB:PCSR - News), a leading financial technology company and provider of independent research to institutional investors, today unveiled BiotechTracker, a subscription service jointly developed by PCS Research Technology and Btech Investor, Inc. Located on the PCS Research Platform at www.pcsresearch.com, BiotechTracker offers clients analytical tools to conduct interactive research, analysis, and valuation of the drug pipelines of biotech and pharmaceutical companies.
BiotechTracker provides clients easy display and search capabilities to develop investment decisions regarding companies that develop pharmaceutical and other therapeutic products. The service includes analysis of events that influence the development of a drug, including clinical and pre-clinical trial data, partnership agreements, related drug information, and regulatory events. This qualitative analysis is coupled with a proprietary model, developed by BiotechTracker and Seraphim Life Sciences Consulting LLC, that use historical results to estimate the probability that developmental drugs will be approved by the FDA. The model, along with projections of approval date, market size, market penetration, and other factors, is used to calculate the value of a company's clinical pipeline.
Commenting on the service, Robert F. Kyle, Executive Vice President of PCS Research Technology, said, "The launch of the BiotechTracker Subscription Service marks yet another successful step for PCS in the institutional research space. Timely insightful healthcare analysis presented in an interactive format appeals to a broad base of our hedge and mutual fund clients. BiotechTracker should undoubtedly revolutionize healthcare research much in the way that PlacementTracker revolutionized PIPE market research."
As part of the official launch, BiotechTracker has rolled-out coverage of the drug pipelines of three high-profile biotechnology companies: Abgenix, EntreMed, and Amylin. Full coverage of the drugs in these companies' pipelines, as well as their valuation models, are available to BiotechTracker subscribers immediately. BiotechTracker expects to rollout coverage of approximately ten more companies' drug pipelines (including Amgen, Genentech, and ImClone) by the end of the year.
About PCS Research Technology, Inc.
PCS Research Technology Inc., formerly DirectPlacement, Inc., is a financial technology company using advanced proprietary technology platforms to distribute financial research, data, and analytics. The Company is leveraging its technology to become a leading single-source provider of independent research for the institutional investment community. Through its wholly owned broker-dealer subsidiary, PCS Securities, Inc., the Company provides independent research and institutional trading services for institutional investors. For more information, please visit the PCS Research Technology website at www.pcsresearch.com.
About Btech Investor, Inc.
Btech Investor, Inc. is an independent research and consulting firm covering the life sciences sector.
Safe Harbor Statement
Statements in this press release that are not statements of
historical or current fact constitute "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act of
1995. Such forward-looking statements involve known and unknown risks,
uncertainties, and other unknown factors that could cause the actual
results of the Company to be materially different from the historical
results or from any future results expressed or implied by such
forward-looking statements. In addition to statements which explicitly
describe such risks and uncertainties, readers are urged to consider
statements labeled with the terms "believes," "belief," "expects,"
"intends," "anticipates," "will," or "plans" to be uncertain and
forward-looking. The forward-looking statements contained herein are
also subject generally to other risks and uncertainties that are
described from time to time in the Company's reports and registration
statements filed with the Securities and Exchange Commission.
PCS Research Technology, Inc. Brian M. Overstreet, 858/200-2350
Source: PCS Research Technology, Inc.